← Back to Search
Pursuit Of A Perfect Insulin
Alexander N Zaykov, J. Mayer, R. DiMarchi
Published 2016 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Insulin remains indispensable in the treatment of diabetes, but its use is hampered by its narrow therapeutic index. Although advances in peptide chemistry and recombinant DNA-based macromolecule synthesis have enabled the synthesis of structurally optimized insulin analogues, the growing epidemics of obesity and diabetes have emphasized the need for diabetes therapies that are more efficacious, safe and convenient. Accordingly, a broad set of drug candidates, targeting hyperglycaemia plus other disease abnormalities, is now progressing through the clinic. The development of an insulin therapy that is responsive to glucose concentration remains an ultimate goal, with initial prototypes now reaching the proof-of-concept stage. Simultaneously, the first alternatives to injectable delivery have progressed to registration.
This paper references
Protein engineering of insulin: Two novel fast-acting insulins [B16Ala]insulin and [B26Ala]insulin
Z. Zhang (2008)
C-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations
K. Polonsky (1984)
Insulin structure and function.
J. Mayer (2007)
supporting acts and new players
Controlling insulin bioavailability by crystal contact engineering
R Hilgenfeld (1992)
Therapeutic insulins and their large-scale manufacture
G. Walsh (2004)
A Review of the
Robert Wolpert (1985)
A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes
L. Kennedy (2007)
Design of an Active Ultrastable Single-chain Insulin Analog
Q. Hua (2008)
Ultrasound-mediated transdermal transport of insulin in vitro through human skin using novel transducer designs.
N. Smith (2003)
Merck to Acquire SmartCells, Inc. Merck Press Releases [online], http://www.merck.com/ licensing/our-partnership/SmartCells-partnership.html
Rewriting medical history: Charles Best and the Banting and Best myth.
M. Bliss (1993)
THE PREPARATION OF INSULIN
C. Best (1925)
Oral administration of insulin by encapsulation within liposomes
H. M. Patel (1976)
Generation of Functional Human Pancreatic β Cells In Vitro
F. Pagliuca (2014)
Monomeric insulins obtained by protein engineering and their medical implications
J. Brange (1988)
Synthesis: A constructive debate
J. Keasling (2012)
Single‐dose pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 in healthy subjects
V. Sinha (2014)
Total synthesis of crystalline bovine insulin.
Y. Kung (1965)
An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice.
W. Holland (2013)
Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM
E. Torlone (2004)
Insulin's direct effects on the liver dominate the control of hepatic glucose production.
D. Edgerton (2006)
Dance 501 inhaled human insulin has a dose-linear response and similar within-subject variability as rapid-acting insulin lispro
E Zijlstra (2015)
Preparation of Crystalline Insulin
R. G. Romans (1940)
Zinc insulin preparations for single daily injection; clinical studies of new preparations with prolonged action.
K. Hallas-Møller (1952)
Expression in Escherichia coli of chemically synthesized genes for human insulin.
D. Goeddel (1979)
A systematic review of the literature
V. Montori (2002)
Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
F. Wang (2012)
Variability of glucose‐lowering effect as a limiting factor in optimizing basal insulin therapy: a review
J. Vora (2013)
Secretion and processing of insulin precursors in yeast.
L. Thim (1986)
Responsive materials for self-regulated insulin delivery.
Weitai Wu (2013)
Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.
J. Xu (2009)
Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care 2013;36(Suppl. 2):S226–S232
J. Vora (2013)
Short‐term intensified insulin treatment in type 2 diabetes: long‐term effects on β‐cell function
R. Retnakaran (2012)
Liver enzyme results from 7 basal insulin peglispro (BIL) clinical trials in T1D and T2D
Oral insulin reloaded a structured approach
E. Zijlstra (2014)
Basal insulin analogues in the management of diabetes mellitus: what progress have we made?
D. Owens (2014)
Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion.
R. Eaton (1983)
J. Neumiller (2012)
Lower Glucose Variability and Hypoglycemia Measured by Continuous Glucose Monitoring With Novel Long-Acting Insulin LY2605541 Versus Insulin Glargine
R. Bergenstal (2014)
Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates
D. Chou (2015)
Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes
I. Hirsch (2012)
Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glulisine
R. Becker (2008)
The pilot study.
C. Baird (2000)
Sanofi to propel inhalable insulin Afrezza into market
Jim Kling (2014)
Bariatric Surgery Versus Intensive Medical Therapy in Obese Patients With Diabetes
P. Schauer (2013)
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
K. Miyawaki (2002)
A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control
V. Bhaskar (2012)
Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention (American
P. Cryer (2012)
T. C. Zion (2010)
Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials
Christopher H. Sorli (2013)
Current challenges in non-invasive insulin delivery systems: a comparative review.
E. Khafagy (2007)
Translating the Diabetes Control and Complications Trial (DCCT) into clinical practice: overcoming the barriers
B. Zinman (1997)
Joslinʼs Diabetes Mellitus
C. Kahn (1995)
Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study
R. Eldor (2013)
Diabetes: Insulin pump therapy for type 2 diabetes mellitus
J. Pickup (2014)
Comparison between closed-loop portal and peripheral venous insulin delivery systems for an artificial endocrine pancreas
T. Sekigami (2004)
Fully convergent chemical synthesis of ester insulin: determination of the high resolution X-ray structure by racemic protein crystallography.
Michal Avital-Shmilovici (2013)
Identification of a Small Molecular Insulin Receptor Agonist With Potent Antidiabetes Activity
Guifen Qiang (2014)
Safety and efficacy of ultra-rapid-acting human insulin formulation BIOD-123 in patients with type 1 diabetes
A Krasner (2014)
OI338GT (NN1953) Phase II trial
Novo Nordisk (2016)
Newer insulin analogs: advances in basal insulin replacement
B. Zinman (2013)
Contrasting weight changes with LY2605541, a novel long‐acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM
S. Jacober (2014)
NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue.
S. Jørgensen (1989)
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
J. Rosenstock (2014)
Insulin-pump therapy for type 1 diabetes mellitus.
I. Blumer (2012)
One-year efficacy and safety of IDegLira in patients with type 2 diabetes
S. Gough (2014)
Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks
L. Schäffer (2003)
Concise synthetic routes to human insulin.
F. Liu (2013)
Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man.
D. Moller (1989)
Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes.
C. Meyer (2004)
Lilly Ends Basal Insulin Peglispro Development Program. Lilly Investor Press Release [online], https://investor.lilly.com/releasedetail
Eli Lilly (2014)
what progress have we made? Diabetes Metab
D. R. Owens (2014)
Insulin Fibrillation and Protein Design: Topological Resistance of Single-Chain Analogs to Thermal Degradation with Application to a Pump Reservoir
Nelson F B Phillips (2012)
Human insulin prepared by recombinant DNA techniques and native human insulin interact identically with insulin receptors.
L. Keefer (1981)
Alternative routes of insulin delivery
D. Owens (2003)
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
T. Vilsbøll (2003)
F. Nabavi (2012)
The Prolongation of Insulin Action
C. Best (1937)
Oral Insulin Delivery: How Far are We?
P. Fonte (2013)
Closed-loop insulin delivery: from bench to clinical practice
R. Hovorka (2011)
Functionally distinct insulin receptors generated by tissue‐specific alternative splicing.
L. Mosthaf (1990)
Agonism and Antagonism at the Insulin Receptor
L. Knudsen (2012)
a multicentre randomised trial
Engineering of Insulin Receptor Isoform-Selective Insulin Analogues
Tine Glendorf (2011)
Design and folding of [GluA4(ObetaThrB30)]insulin ("ester insulin"): a minimal proinsulin surrogate that can be chemically converted into human insulin.
Y. Sohma (2010)
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.
L. Sjöström (2004)
Insulin analogues with chlorinated amino acids
마이클 웨이스 (2010)
PEGylated insulin Lispro, (LY2605541)—a new basal insulin analogue
T. M. Caparrotta (2014)
Combined Use of Regular and Crystalline Protamine (NPH) Insulins in the Treatment of Severe Diabetes
W. Oakley (1966)
Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes
F. Smeeton (2009)
leveraging hydrodynamic size to develop a novel basal insulin
Efficacy and safety of insulin glulisine in patients with type 1 diabetes.
M. Dreyer (2005)
advances in basal insulin replacement
Anti-obesity drugs: past, present and future
R. Rodgers (2012)
The amino-acid sequence in the phenylalanyl chain of insulin. 2. The investigation of peptides from enzymic hydrolysates.
F. Sanger (1951)
The amino-acid sequence in the phenylalanyl chain of insulin. I. The identification of lower peptides from partial hydrolysates.
F. Sanger (1951)
Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic beta cells.
B. Leibiger (2001)
Insulin Pump Therapy for Type 2 Diabetes Mellitus Accompanied with Community-acquired Pneumonia
Yang Xiao-hon (2010)
Can Diabetes Be Surgically Cured? Long-Term Metabolic Effects of Bariatric Surgery in Obese Patients with Type 2 Diabetes Mellitus
S. Brethauer (2013)
Signalling by insulin and IGF receptors: supporting acts and new players.
K. Siddle (2011)
A history of blood glucose meters and their role in self-monitoring of diabetes mellitus
S. Clarke (2012)
From bench to MS bedside: Challenges translating biomarker discovery to clinical practice
S. Rajasekharan (2012)
Superior glycaemic control with once‐daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial
Y. Onishi (2013)
The effect of portal and peripheral insulin delivery on carbohydrate and lipid metabolism in a miniature pig model of human IDDM
J. Canavan (1997)
Reversible insulin self-assembly under carbohydrate control.
T. Hoeg-Jensen (2005)
Short-Term Intensive Therapy in Newly Diagnosed Type 2 Diabetes Partially Restores Both Insulin Sensitivity and β-Cell Function in Subjects With Long-Term Remission
Y. Hu (2011)
Combining GLP‐1 receptor agonists with insulin: therapeutic rationales and clinical findings
J. Holst (2013)
Oral insulin – a review of current status
H. Iyer (2010)
A randomized crossover study of bee sting therapy for multiple sclerosis
T. Wesselius (2005)
The synthesis of bovine insulin by the solid phase method.
A. Marglin (1966)
The Lente Insulins
K. Hallas-Mø (1956)
Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group.
J. Anderson (1997)
The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin
S. Havelund (2004)
The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
S. Garg (2010)
Glucose dependent release of insulin from glucose sensing insulin derivatives
T Hoeg-Jensen (2008)
Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.
B. Kerr (2009)
Biology of incretins: GLP-1 and GIP.
L. Baggio (2007)
Insulin therapy for management of type 2 diabetes mellitus: strategies for initiation and long-term patient adherence.
Steven H. Barag (2011)
Perfusion-decellularized pancreas as a natural 3D scaffold for pancreatic tissue and whole organ engineering.
Saik-Kia Goh (2013)
A synthetic route to human insulin using isoacyl peptides.
F. Liu (2014)
Novel hepatoselective insulin analog: studies with a covalently linked thyroxyl-insulin complex in humans.
F. Shojaee-Moradie (2000)
randomized, parallel, treat to target trial comparing insulin detemir with NPH insulin as add on therapy to oral glucoselowering drugs in insulin-naive people with type 2 diabetes
K Hermansen (2006)
Insulin degludec: overview of a novel ultra long‐acting basal insulin
S. Gough (2013)
The lente insulins.
K. Hallas-Møller (1956)
Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes
J. Rosenstock (2013)
Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
P. Home (2014)
Backbone cyclic insulin
A. Andersen (2010)
Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes
K. Birkeland (2011)
GLP 1 and GIP
L. L. Baggio (2007)
Insulin Peptides. X. The Synthesis of the B-Chain of Insulin and Its Combination with Natural or Synthetis A-Chin to Generate Insulin Activity
P. Katsoyannis (1964)
Receptor-isoform-selective insulin analogues give tissue-preferential effects.
S. Vienberg (2011)
Single-chain insulin agonists exhibiting high activity at the insulin receptor
Total Synthesis of desB30 Insulin Analogues by Biomimetic Folding of Single‐Chain Precursors
A. P. Tofteng (2008)
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long‐Term Complications in Insulin‐Dependent Diabetes Mellitus
D. Nathan (1993)
Differential Pathway Coupling of the Activated Insulin Receptor Drives Signaling Selectivity by XMetA, an Allosteric Partial Agonist Antibody
Daniel H Bedinger (2015)
A Breath of Fresh Air (review)
L. Lent (2003)
Practical Aspects of Insulin Pen Devices
T. Pearson (2010)
Mechanism of action of insulin and insulin analogues
C. Tompkins (2004)
Insulin Pens and New Ways of Insulin Delivery
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
S. Gough (2014)
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD‐ON)
C. Mathieu (2014)
The amino-acid sequence in the glycyl chain of insulin. II. The investigation of peptides from enzymic hydrolysates.
F. Sanger (1953)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
B. Finan (2013)
Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.
A. Belfiore (2009)
Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice.
V. Gault (2011)
Preprandial oral insulin (ORMD-0801) reduces rapid-acting insulin requirements and fasting glucose levels in T1DM patients (poster)
M. Kidron (2015)
strategies for initiation and longterm patient adherence
Chemically and thermodynamically stable insulin analogues and improved methods for their production
M. H. Stowell (2015)
Proinsulin-Transferrin Fusion Protein as a Novel Long-Acting Insulin Analog for the Inhibition of Hepatic Glucose Production
Y. Wang (2014)
The use of stem cells for pancreatic regeneration in diabetes mellitus
L. Bouwens (2013)
Insulin pumps: from inception to the present and toward the future
F. Alsaleh (2010)
Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects
R. Henry (2014)
synthesis, structure, and therapeutic implications
Novo Nordisk Receives FDA Approval for Tresiba® (insulin degludec injection) for Adults with Type 1 and Type 2 Diabetes
Novo Nordisk (2015)
Past, present--and future?
D. Holdstock (2005)
Chemical synthesis of insulin analogs through a novel precursor.
Alexander N Zaykov (2014)
Novel very long-acting insulin analog (HM12470) with potential for onceweekly dosing has a favorable PK, PD and mitogenic profile. American Diabetes Association’s 74th Scientific Sessions [online
Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial
J. Rosenstock (2010)
Agonistic aptamer to the insulin receptor leads to biased signaling and functional selectivity through allosteric modulation
Na-Oh Yunn (2015)
Synergistic action of PE0139, a super-long-acting basal insulin & PB1023 a weekly GLP1 receptor agonist
S. Arnold (2015)
K. H. Wolf (2011)
results of a Phase 3, open-label, randomised, 26 week, treat to target trial in insulin-naive patients with type 2 diabetes
Is There a Need for a Better Basal Insulin
R. Guthrie (2001)
Therapeutic agents comprising insulin amino acid sequences
조엣 제임스 (2012)
Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
J. Rosenstock (2001)
[Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin
D. C. Howey (1994)
In Vivo Deactivation of Proinsulin Action on Glucose Disposal and Hepatic Glucose Production in Normal Man
H. Glauber (1986)
how far are we? J
P. Fonte (2013)
W99-S32 a soluble, basal insulin analog
S Myers (1995)
One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial
S. Gough (2015)
Cell factories for insulin production
N. Baeshen (2014)
Human insulin from recombinant DNA technology.
I. Johnson (1983)
FDA dashes Novo's hopes
E. Dorey (2013)
Human Insulin: Facile Synthesis by Modification of Porcine Insulin
M. A. Ruttenberg (1972)
Peptide and Protein Design for Biopharmaceutical Applications
W. Kazmierski (2010)
Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
R. Balena (2013)
Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010.
K. Lipska (2014)
Closed-loop system in the management of diabetes: past, present, and future.
V. Shah (2014)
Discovery of high potency, single-chain insulin analogs with a shortened B-chain and nonpeptide linker.
Zachary P Kaur (2013)
Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial
G. Fulcher (2014)
A 7-year follow-up retrospective, international, multicenter study of insulin pump therapy in children and adolescents with type 1 diabetes
C. Mameli (2013)
Use of PKPD model to design and analyze results of a euglycemic clamp study for a very long-acting insulin analogue HM12470
Y Huh (2015)
Activation of the Insulin Receptor by Insulin and a Synthetic Peptide Leads to Divergent Metabolic and Mitogenic Signaling and Responses*
M. Jensen (2007)
Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes.
Erin C Cobry (2010)
The role of leptin in glucose homeostasis
H. Denroche (2012)
Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.
P. Home (1998)
Insulin Across Respiratory Mucosae by Aerosol Delivery
F. W. Wigley (1971)
Pfizer dumps Exubera
G. Mack (2007)
Hepatoselectivity and the evolution of insulin
R. Herring (2014)
Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial
P. Home (2000)
The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options
L. Fani (2014)
Changes in Glucose and Fat Metabolism in Response to the Administration of a Hepato-Preferential Insulin Analog
D. Edgerton (2014)
Alternative splicing of human insulin receptor messenger RNA.
S. Seino (1989)
Emerging micro- and nanotechnology based synthetic approaches for insulin delivery.
Ran Mo (2014)
Total synthesis of crystalline bovine insulin.
Kung Yt (1965)
Organization of glucose-responsive systems and their properties.
Q. Wu (2011)
Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans.
J. Meier (2005)
Development of a long-acting insulin analog using albumin fusion technology.
A. Duttaroy (2005)
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
I. Jonassen (2012)
linear dose-response and faster absorption than insulin Lispro (LIS)
GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
S. Kim (2012)
Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
R. Becker (2005)
Financial report for the period 1 January 2014
Novo Nordisk (2014)
ON THE PREPARATION OF INSULIN
M. Somogyi (1924)
This paper is referenced by
Novel Methods for the Chemical Synthesis of Insulin Superfamily Peptides and of Analogues Containing Disulfide Isosteres.
M. Hossain (2017)
Analysis of Insulin Analogs and the Strategy of Their Further Development
O. Selivanova (2018)
Responsive boron biomaterials and their biomedical applications
W. Chen (2020)
Calculating the absolute binding free energy of the insulin dimer in an explicit solvent
Qiankun Gong (2020)
Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug
A. Kwiatkowska (2019)
BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats
C. V. M. F. Nascimento (2019)
Therapeutic medications against diabetes: What we have and what we expect.
C. Hu (2018)
pH- and Amylase-Responsive Carboxymethyl Starch/Poly(2-isobutyl-acrylic acid) Hybrid Microgels as Effective Enteric Carriers for Oral Insulin Delivery.
L. Liu (2018)
Comparison of glucose variability in patients with type 2 diabetes administrated glargine with needle-free jet injector and conventional insulin pen
Ying Sun (2020)
Synthetic Advances in Insulin-like Peptides Enable Novel Bioactivity.
F. Liu (2017)
Trans-toxin ion-sensitivity of charybdotoxin-blocked potassium-channels reveals unbinding transitional states
Hans Moldenhauer (2019)
Characterization of an insulinotropic peptide from skin secretions of Odorrana andersonii
Wei-Jie Shang (2017)
Recent advances in the chemical synthesis of insulin and related peptides.
F. Brunel (2020)
Development of glucose-responsive ‘smart’ insulin systems
N. Rege (2017)
Display of Single-Chain Insulin-like Peptides on a Yeast Surface.
Mi-Young Jeong (2019)
Improving long‐term subcutaneous drug delivery by regulating material‐bioenvironment interaction☆
W. Chen (2018)
A glucose-responsive insulin therapy protects animals against hypoglycemia.
R. Yang (2018)
Insulin analogues in type 1 diabetes mellitus: getting better all the time
C. Mathieu (2017)
Closed-loop control systems – The quest for precision therapies for diabetes
Mingqi Xie (2017)
Characterization of viral insulins reveals white adipose tissue-specific effects in mice
Martina Chrudinová (2020)
O-GlcNAc engineering of GPCR peptide-agonists improves their stability and in vivo activity.
Paul M. Levine (2019)
Small Scaffolds, Big Potential: Developing Miniature Proteins as Therapeutic Agents
Justin M Holub (2017)
Molecular evolution of peptides by yeast surface display technology.
Sara Linciano (2019)
Long‐Lasting Designer Insulin with Glucose‐Dependent Solubility Markedly Reduces Risk of Hypoglycemia
Yibo Qiu (2019)
Strategies for improving diabetic therapy via alternative administration routes that involve stimuli-responsive insulin-delivering systems.
Yu-Jung Lin (2018)
Clinical Evaluation of MK‐2640: An Insulin Analog With Glucose‐Responsive Properties
A. Krug (2019)
Insulin-like Growth Factor 1 Analogs Clicked in the C Domain: Chemical Synthesis and Biological Activities.
K. Macháčková (2017)
Human Designer Cells: From Remote-Controlled Gene Regulation to Self-sufficient Therapeutic Biocomputers
Mingqi Xie (2017)
Glucose-lowering therapies in type 2 diabetes: Opportunities and challenges for peptides
C. Bailey (2018)
Replacement of ProB28 by pipecolic acid protects insulin against fibrillation and slows hexamer dissociation
K. Y. Fang (2019)
Engineering the vasculature for islet transplantation.
D. Bowers (2019)
β-cell–mimetic designer cells provide closed-loop glycemic control
Mingqi Xie (2016)See more